AWKN — Awakn Life Sciences Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Annual income statement for Awakn Life Sciences, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | C2023 January 31st | 2024 January 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0.236 | 0 | 0.087 |
| Cost of Revenue | ||||
| Gross Profit | 0 | -0.277 | — | — |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 1.1 | 11.2 | 5.28 | 4.01 |
| Operating Profit | -1.1 | -11 | -5.28 | -3.93 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -1.11 | -16.5 | -4.96 | -3.67 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -1.11 | -16.5 | -4.96 | -3.67 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -0.945 | -15.9 | -9.14 | -5.01 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.945 | -15.9 | -9.14 | -5.01 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.019 | -0.673 | -0.197 | -0.126 |
| Dividends per Share |